View in EDS

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.

Saved in:
Bibliographic Details
Title: Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
Authors: Liu JF; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston joyce_liu@dfci.harvard.edu., Moore KN; Division of Gynecologic Oncology, Stephenson Oklahoma Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City., Birrer MJ; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston., Berlin S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston.; Department of Oncology, New England Cancer Care Specialists, Kennebunk., Matulonis UA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston., Infante JR; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville., Wolpin B; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston., Poon KA; Early Development, Genentech, South San Francisco, USA., Firestein R; Early Development, Genentech, South San Francisco, USA., Xu J; Early Development, Genentech, South San Francisco, USA., Kahn R; Early Development, Genentech, South San Francisco, USA., Wang Y; Early Development, Genentech, South San Francisco, USA., Wood K; Early Development, Genentech, South San Francisco, USA., Darbonne WC; Early Development, Genentech, South San Francisco, USA., Lackner MR; Early Development, Genentech, South San Francisco, USA., Kelley SK; Early Development, Genentech, South San Francisco, USA., Lu X; Early Development, Genentech, South San Francisco, USA., Choi YJ; Early Development, Genentech, South San Francisco, USA., Maslyar D; Early Development, Genentech, South San Francisco, USA., Humke EW; Early Development, Genentech, South San Francisco, USA., Burris HA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville.
Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2016 Nov; Vol. 27 (11), pp. 2124-2130.
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 27793850
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Liu+JF%22">Liu JF</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston joyce_liu@dfci.harvard.edu.<br /><searchLink fieldCode="AU" term="%22Moore+KN%22">Moore KN</searchLink>; Division of Gynecologic Oncology, Stephenson Oklahoma Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City.<br /><searchLink fieldCode="AU" term="%22Birrer+MJ%22">Birrer MJ</searchLink>; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.<br /><searchLink fieldCode="AU" term="%22Berlin+S%22">Berlin S</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston.; Department of Oncology, New England Cancer Care Specialists, Kennebunk.<br /><searchLink fieldCode="AU" term="%22Matulonis+UA%22">Matulonis UA</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston.<br /><searchLink fieldCode="AU" term="%22Infante+JR%22">Infante JR</searchLink>; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville.<br /><searchLink fieldCode="AU" term="%22Wolpin+B%22">Wolpin B</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston.<br /><searchLink fieldCode="AU" term="%22Poon+KA%22">Poon KA</searchLink>; Early Development, Genentech, South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Firestein+R%22">Firestein R</searchLink>; Early Development, Genentech, South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Xu+J%22">Xu J</searchLink>; Early Development, Genentech, South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Kahn+R%22">Kahn R</searchLink>; Early Development, Genentech, South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Wang+Y%22">Wang Y</searchLink>; Early Development, Genentech, South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Wood+K%22">Wood K</searchLink>; Early Development, Genentech, South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Darbonne+WC%22">Darbonne WC</searchLink>; Early Development, Genentech, South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Lackner+MR%22">Lackner MR</searchLink>; Early Development, Genentech, South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Kelley+SK%22">Kelley SK</searchLink>; Early Development, Genentech, South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Lu+X%22">Lu X</searchLink>; Early Development, Genentech, South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Choi+YJ%22">Choi YJ</searchLink>; Early Development, Genentech, South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Maslyar+D%22">Maslyar D</searchLink>; Early Development, Genentech, South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Humke+EW%22">Humke EW</searchLink>; Early Development, Genentech, South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Burris+HA%22">Burris HA</searchLink>; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229007735%22">Annals of oncology : official journal of the European Society for Medical Oncology</searchLink> [Ann Oncol] 2016 Nov; Vol. 27 (11), pp. 2124-2130.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9007735 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1569-8041 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209237534%22">09237534 </searchLink><i>NLM ISO Abbreviation: </i>Ann Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=27793850
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/annonc/mdw401
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2124
    Titles:
      – TitleFull: Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Liu JF
      – PersonEntity:
          Name:
            NameFull: Moore KN
      – PersonEntity:
          Name:
            NameFull: Birrer MJ
      – PersonEntity:
          Name:
            NameFull: Berlin S
      – PersonEntity:
          Name:
            NameFull: Matulonis UA
      – PersonEntity:
          Name:
            NameFull: Infante JR
      – PersonEntity:
          Name:
            NameFull: Wolpin B
      – PersonEntity:
          Name:
            NameFull: Poon KA
      – PersonEntity:
          Name:
            NameFull: Firestein R
      – PersonEntity:
          Name:
            NameFull: Xu J
      – PersonEntity:
          Name:
            NameFull: Kahn R
      – PersonEntity:
          Name:
            NameFull: Wang Y
      – PersonEntity:
          Name:
            NameFull: Wood K
      – PersonEntity:
          Name:
            NameFull: Darbonne WC
      – PersonEntity:
          Name:
            NameFull: Lackner MR
      – PersonEntity:
          Name:
            NameFull: Kelley SK
      – PersonEntity:
          Name:
            NameFull: Lu X
      – PersonEntity:
          Name:
            NameFull: Choi YJ
      – PersonEntity:
          Name:
            NameFull: Maslyar D
      – PersonEntity:
          Name:
            NameFull: Humke EW
      – PersonEntity:
          Name:
            NameFull: Burris HA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2016 Nov
              Type: published
              Y: 2016
          Identifiers:
            – Type: issn-electronic
              Value: 1569-8041
          Numbering:
            – Type: volume
              Value: 27
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: Annals of oncology : official journal of the European Society for Medical Oncology
              Type: main
ResultId 1